Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae
Journal of Antimicrobial Chemotherapy · 03.04.2023 · 78 (4) · 991-999
DOI: 10.1093/jac/dkad033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.02.2023. Verfasst von Yuki Igarashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan. Hauptthemen laut MEDLINE: Aztreonam, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED.
Abstract (Originalsprache)
Background
Nacubactam, a new β-lactamase inhibitor with antibacterial activity, is being developed as a single drug to be co-administered with cefepime or aztreonam. However, determining pharmacokinetics/pharmacodynamics (PK/PD) parameters in β-lactam/β-lactamase inhibitor combinations remains challenging. We aimed to establish a practical PK/PD analysis method for aztreonam/nacubactam that incorporates instantaneous MIC (MICi).
Methods
Based on chequerboard MIC measurements, MICi of aztreonam against carbapenemase-producing Klebsiella pneumoniae in the presence of nacubactam was simulated.
Results
The mean change in the bacterial count of thigh-infected mice in an in vivo PD study was plotted based on %fT>MICi and analysed using the inhibitory effect sigmoid Imax model. fT>MICi calculated from the PK experiments showed a high correlation with the in vivo bactericidal effect, suggesting that fT>MICi is the optimal PK/PD parameter for aztreonam/nacubactam. The target values of fT>MICi achieving growth inhibition, 1 log10 kill and 2 log10 kill, were 22, 38% and 75%, respectively.
Conclusions
The PK/PD analysis method proposed in this study is promising for determining practical PK/PD parameters in combination therapy. In addition, this is the first report of aztreonam/nacubactam showing a potent in vivo therapeutic effect against NDM-producing K. pneumoniae.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
- Discipline of Pharmacy, Curtin Medical School, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, Western Australia 6845, Australia.
ORCID-Profile: Yuki Enoki, Kazuaki Taguchi
Förderung
- AMED
Zitieren
APA
Igarashi, Y., Takemura, W., Liu, X., Kojima, N., Morita, T., Chuang, V. T. G., Enoki, Y., Taguchi, K., & Matsumoto, K. (2023). Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae. Journal of Antimicrobial Chemotherapy, 78(4), 991-999. https://doi.org/10.1093/jac/dkad033
Vancouver
Igarashi Y, Takemura W, Liu X, Kojima N, Morita T, Chuang VTG, et al. Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae. Journal of Antimicrobial Chemotherapy. 2023;78(4):991-999. doi:10.1093/jac/dkad033
BibTeX
@article{Igarashi2023,
author = {Igarashi, Yuki and Takemura, Wataru and Liu, Xiaoxi and Kojima, Nana and Morita, Takumi and Chuang, Victor Tuan Giam and Enoki, Yuki and Taguchi, Kazuaki and Matsumoto, Kazuaki},
title = {Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {4},
pages = {991--999},
doi = {10.1093/jac/dkad033}
}
EUVIMED